
    
      This Phase 3, open-label, safety and efficacy study will be performed at sites in North
      America, Europe, and Israel. The study will enroll up to approximately 208 participants with
      nmCF who participated in a previous Phase 3 study of ataluren (PTC124-GD-009-CF [Study 009],
      NCT00803205). Participants will receive study drug 3 times per day (TID) (at breakfast,
      lunch, and dinner) for approximately 48 weeks (approximately 1 year). Study assessments will
      be performed at clinic visits every 8 weeks.
    
  